MarketWise: Moderna surges 177 percent on historic phase 3 mRNA cancer therapy results as biotech rallies

MarketWise: Moderna surges 177 percent on historic phase 3 mRNA cancer therapy results as biotech rallies
Moderna jumps as biotech rallies

Moderna soared 177 percent after delivering positive phase 3 results for its personalized mRNA cancer therapy, marking the first phase 3 readout of its kind and fueling a surge across the biotech sector.

Merck hit a record high on the news while other cancer vaccine stocks also advanced sharply. The milestone result reinforces rising momentum in mRNA-based cancer treatments, attracting investor attention and potentially reshaping the biotech landscape. As positive trial data revive optimism, industry analysts are closely watching additional contenders developing mRNA cancer vaccines.

Recent coverage by the author included AMD’s $5 billion AI infrastructure agreement with Anthropic, increasing competitive pressure on Nvidia (link). Earlier, Bitdeer unveiled a $4.7 billion plan to pivot from cryptocurrency mining to building AI data centers through a major Anthropic partnership (link). These developments highlight significant capital allocation shifts within the technology and biotech industries.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.